Icon times
GSK Pharma Q1FY22 Result Analysis

GSK Pharma Q1FY22 Result Analysis

Published on 20 August 2021 .Views 45 .Comments 0
Share On
GSK Pharma registered strong YOY revenue growth of around 22% but declined sequentially by 3%. Growth was majorly motivated by the dermatology, anti-infectives & pain segment. Margins stood under pressure due to high marketing expenses."

Please find attached for detailed analysis. here
private article suscription area icon

You like to know more. We like that!

Please subscribe Model Portfolio Plan to get access of all premium model portfolio articles Only at Rs. 9,999.00/Year.

Please login to view this free article.

This blog is available only for logged in users, please register and get access to view this article.

Recently Uploaded

premium Premium
free Free
Chat on WhatsApp
Caret UP Arrow
InvestYadnya Support
Typically replies in minutes
InvestYadnya Support
Hi there
Welcome to InvestYadnya.
We are available to assist you on WhatsApp.
Please click on the button below to chat with us.
(10 AM to 7 PM IST)
Chat with InvestYadnya